RituxiRel-Rituximab Injection 500 mg / Ритуксимаб 500 мг

Для получения подробной информации нажмите кнопку "Консультация"

Также вы можете связаться с менеджером через мессенджеры

Торговая марка: Rituxirel
Состав: ритуксимаб
Крепость: 500 мг
Изготовлено: Reliance Life Sciences
Упаковка: 100 мг в 1 флаконе.


Rituxirel 500mg is an anticancer medicine which prevents the growth and spread of cancer cells in the body. Rituxirel 500mg injection also indicated for the treatment of Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drugs like methotrexate is used for rheumatoid arthritis symptoms in adult treatment. Rituxirel 500mg with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.


Rituxirel 500mg and hyaluronidase human injection are given alone or combination with other drugs to treat certain types of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (cancer start in WBC).
Rituxirel 500mg injection is also used with methotrexate (Otrexup, Rasuvo, Xatmep, others) for the treatment rheumatoid arthritis symptoms in adults that have been already treated with some type of regimen known as tumor necrosis factor (TNF) inhibitor.
Rituxirel 500mg is a type in a classification of drugs called monoclonal antibodies. Rituxirel 500mg is used to killing cancer cells to treat NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by stopping the activity of the part of the immune system that will damage the joints, veins, and other blood vessels and cause damage to organs (heart and lungs).


Rituxirel 500mg injection is a type of class called as monoclonal antibody and which is a new type of «targeted» cancer treatment and an integral part of the body’s immune system. Naturally the body build antibodies in along with to an antigen which has entered the body and attach to the antigen for destruction by the immune system.
An essential cells only aimed by monoclonal antibiotics, they may leads to less toxicity to healthy cell and it is usually treatment recommended only for cancers in which antigens (and the respective antibodies) have been already identified.
Rituxirel 500mg works by linking to the CD20 antigen on normal and malignant B-cells. Hence the body’s essential immune security is initiated to attack and kill the marked B-cells. Stem cells i.e. young cells in the bone marrow which will grow into the various cell types and do not have the CD20 antigen. After treatment, CD20 antigen allows healthy B-cells to multiply